Renaissance Technologies LLC lifted its holdings in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 104.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 186,100 shares of the company’s stock after purchasing an additional 95,000 shares during the quarter. Renaissance Technologies LLC owned about 0.40% of Amphastar Pharmaceuticals worth $3,581,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the company. SG Americas Securities LLC acquired a new position in Amphastar Pharmaceuticals in the second quarter valued at approximately $161,000. Schwab Charles Investment Management Inc. lifted its stake in Amphastar Pharmaceuticals by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 194,375 shares of the company’s stock valued at $2,967,000 after buying an additional 11,626 shares during the period. BlackRock Inc. raised its position in shares of Amphastar Pharmaceuticals by 5.9% during the second quarter. BlackRock Inc. now owns 5,720,183 shares of the company’s stock worth $87,291,000 after purchasing an additional 318,360 shares during the period. Legal & General Group Plc raised its position in shares of Amphastar Pharmaceuticals by 9.1% during the second quarter. Legal & General Group Plc now owns 71,656 shares of the company’s stock worth $1,100,000 after purchasing an additional 5,976 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of Amphastar Pharmaceuticals by 5.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,769,533 shares of the company’s stock worth $27,004,000 after purchasing an additional 84,085 shares during the period. 44.72% of the stock is owned by hedge funds and other institutional investors.
AMPH has been the topic of a number of research reports. TheStreet raised Amphastar Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Friday, January 11th. BidaskClub lowered Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Needham & Company LLC set a $25.00 target price on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, November 9th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, November 9th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $26.00 target price on shares of Amphastar Pharmaceuticals in a research report on Wednesday, November 14th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Amphastar Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $23.60.
NASDAQ AMPH opened at $21.94 on Friday. The firm has a market capitalization of $1.01 billion, a P/E ratio of 109.70, a P/E/G ratio of 1.16 and a beta of 1.36. Amphastar Pharmaceuticals Inc has a 12 month low of $14.40 and a 12 month high of $22.74. The company has a quick ratio of 1.34, a current ratio of 2.02 and a debt-to-equity ratio of 0.10.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Thursday, November 8th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. The business had revenue of $75.54 million during the quarter, compared to analyst estimates of $76.84 million. Amphastar Pharmaceuticals had a positive return on equity of 2.80% and a negative net margin of 2.33%. Amphastar Pharmaceuticals’s quarterly revenue was up 30.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.07 EPS. Equities analysts expect that Amphastar Pharmaceuticals Inc will post -0.06 EPS for the current year.
In other Amphastar Pharmaceuticals news, insider Jason B. Shandell sold 16,630 shares of the company’s stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $22.44, for a total value of $373,177.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Yakob Liawatidewi sold 17,808 shares of the company’s stock in a transaction on Friday, November 9th. The shares were sold at an average price of $20.97, for a total value of $373,433.76. Following the completion of the transaction, the senior vice president now owns 46,763 shares of the company’s stock, valued at approximately $980,620.11. The disclosure for this sale can be found here. Insiders sold a total of 452,062 shares of company stock valued at $9,611,906 over the last three months. 31.50% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2019/01/20/amphastar-pharmaceuticals-inc-amph-stake-increased-by-renaissance-technologies-llc.html.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Read More: What are Closed-End Mutual Funds?
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH).
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.